World-class Performance with Assistance of Artificial Intelligence

STOCKHOLM, Dec. 12, 2019 /PRNewswire/ — In the latest version of Ortoma Treatment Solution, OTS 4, Ortoma has introduced support of Artificial Intelligence. The system drastically reduces the time needed for pre-operatively planning of a hip implant in 3D, which has created a big interest for the company’s unique solution. 

Performance has been a focus area during the development of the latest version of Ortoma Treatment Solution (OTS). With OTS 4, an automatic AI-analysis, which forms the basis for the pre-operative planning, is made. The analysis does not take more than about 30 seconds and includes a suggestion for suitable implant and its optimized position. The surgeon can adjust and verify the result in a simple and intuitive workflow, which only takes a few minutes. This can be compared to other systems, which can take up to 30 minutes to perform the same process.

Linus Byström, CEO, comments: “The upgrade of OTS with support of AI exceeds our high ambitions. A pre-operative planning in 3D can now be done substantially quicker than before. It contributes to consistent and optimal result of the treatment outcome.”

OTS 4 with support of AI is CE marked for the European market, and surgeries where the system was used have been performed in Sweden. The company is planning to file an application for marketing approval in USA and selected markets in Asia. Prioritization between countries is on-going.

Ortoma Treatment Solution™ – careful planning and precise surgery.

For more information, please contact:
Ortomas CEO Linus Byström or Chairman of the board Gunnar Németh
mail: info@ortoma.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/ortoma/r/world-class-performance-with-assistance-of-artificial-intelligence,c2988427

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/world-class-performance-with-assistance-of-artificial-intelligence-300973810.html

SOURCE Ortoma

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…

2 hours ago

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

5 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

8 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

11 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

11 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

11 hours ago